Drs. Tristan John Vaughan and Gail Wasserman Included in 2011 PharmaVOICE 100
MedImmune announced today that two of its scientists—Tristan John Vaughan, Ph.D., senior director of lead generation and Gail Wasserman, Ph.D., senior vice president of biopharmaceutical development—have been recognized in the PharmaVOICE 100, an annual list of the most inspiring people in the life sciences industry.
Established seven years ago by PharmaVOICE magazine, the PharmaVOICE 100 recognizes professionals for their positive contributions to the life-sciences industry. Honorees are nominated by the publication's readers. Drs. Vaughan and Wasserman were selected for the positive contributions they have made to MedImmune and to their communities, as well as the motivation they provide to colleagues and peers.
"We are proud to have the inspiring work of Drs. Vaughan and Wasserman acknowledged by PharmaVOICE, as they exemplify the spirit of innovation that is central to MedImmune's mission," said Peter Greenleaf, MedImmune's president. "They demonstrate the tireless commitment of our researchers to deliver life-changing products to help patients with unmet medical needs."
Among achievements throughout his career, Dr. Vaughan has played a key role in the discovery and development of innovative first-in-class products, including the first fully human antibody to reach the market as well as the first new treatment option for patients with systemic lupus erythematosus in more than 50 years. Today, Dr. Vaughan leads a team of more than 80 employees in MedImmune's Cambridge, UK facility where he and his colleagues continue to refine the technologies that have successfully delivered drugs that make a meaningful difference to patients.
Dr. Wasserman's work has also had a significant impact on the health of patients around the world. Her pioneering development work contributed to the introduction of the first monoclonal antibody approved by the U.S. Food and Drug Administration to help prevent an infectious disease. Today, Dr. Wasserman leads a team of 700 employees worldwide, enabling new technologies to be developed and delivered to patients. During her 20-year tenure at MedImmune, the company's pipeline has grown from just a few molecules to more than 100 drug candidates in development today.
MedImmune, the global biologics unit for AstraZeneca PLC, has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. For more information, visit MedImmune's website at www.medimmune.com.